For example, in a study of 31 patients with stage III or IV HER2+ breast cancer who received 6 monthly vaccinations consisting of a T helper epitope from HER2 protein plus GM-CSF, 92% of the patients demonstrated HER2 immunity as measured by T cell proliferation. The gene discussed is ERBB2; the disease is breast cancer.